BidaskClub upgraded shares of Horizon Therapeutics (NASDAQ:HZNP) from a sell rating to a hold rating in a report released on Thursday morning, BidAskClub reports.
Several other research analysts also recently commented on the stock. Piper Jaffray Companies set a $195.00 target price on shares of Cummins and gave the stock a buy rating in a research note on Thursday, April 4th. Mizuho set a $27.00 target price on shares of Horizon Therapeutics and gave the stock a hold rating in a research note on Wednesday, May 8th. TheStreet downgraded shares of Worthington Industries from a b- rating to a c+ rating in a research note on Monday, June 10th. Cantor Fitzgerald lifted their target price on shares of Horizon Therapeutics from $26.00 to $32.00 and gave the stock a buy rating in a research note on Tuesday, April 2nd. Finally, BMO Capital Markets set a $13.00 target price on shares of Vale and gave the stock a hold rating in a research note on Thursday, April 4th. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Horizon Therapeutics has an average rating of Buy and a consensus price target of $31.91.
Shares of HZNP opened at $24.10 on Thursday. The company has a market cap of $4.46 billion, a price-to-earnings ratio of 11.48, a price-to-earnings-growth ratio of 1.39 and a beta of 1.03. The company has a current ratio of 1.74, a quick ratio of 1.68 and a debt-to-equity ratio of 0.90. Horizon Therapeutics has a fifty-two week low of $16.56 and a fifty-two week high of $29.44. The business has a 50 day simple moving average of $23.88.
Horizon Therapeutics (NASDAQ:HZNP) last announced its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported $0.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.10 by $0.20. The firm had revenue of $280.00 million during the quarter, compared to analyst estimates of $238.35 million. Horizon Therapeutics had a net margin of 3.79% and a return on equity of 33.57%. The business’s quarterly revenue was up 25.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.03 EPS. Equities research analysts forecast that Horizon Therapeutics will post 1.62 EPS for the current year.
In other Horizon Therapeutics news, insider Jeff Kent sold 3,620 shares of the business’s stock in a transaction on Wednesday, June 5th. The shares were sold at an average price of $24.64, for a total transaction of $89,196.80. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Vikram Karnani sold 13,111 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $25.02, for a total transaction of $328,037.22. The disclosure for this sale can be found here. 4.10% of the stock is currently owned by insiders.
Institutional investors have recently modified their holdings of the business. Regent Investment Management LLC increased its position in Horizon Therapeutics by 71.7% during the 1st quarter. Regent Investment Management LLC now owns 90,150 shares of the biopharmaceutical company’s stock valued at $2,383,000 after purchasing an additional 37,660 shares during the period. LPL Financial LLC purchased a new stake in shares of Horizon Therapeutics in the 4th quarter worth about $504,000. Signition LP purchased a new stake in shares of Horizon Therapeutics in the 1st quarter worth about $232,000. GAM Holding AG purchased a new stake in shares of Horizon Therapeutics in the 1st quarter worth about $283,000. Finally, Nisa Investment Advisors LLC grew its position in shares of Horizon Therapeutics by 57.0% in the 1st quarter. Nisa Investment Advisors LLC now owns 34,534 shares of the biopharmaceutical company’s stock worth $913,000 after buying an additional 12,539 shares during the period. 89.09% of the stock is currently owned by institutional investors and hedge funds.
About Horizon Therapeutics
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Featured Story: What is the return on assets formula?
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.